Elekta Introduces Groundbreaking Image Guidance Capabilities Integrated with Versa HD Cancer Treatment System
New technology enables real-time X-ray monitoring of internal motion during radiotherapy delivery
CRAWLEY, England, Sept. 11, 2013 /PRNewswire/ — Integrated with Versa HD(TM) linear accelerator, Elekta has introduced new intra-fraction imaging capabilities within its X-ray Volume Imaging (XVI) system. During treatment, XVI now provides the tools to monitor and manage internal motion, supporting the clinician’s efforts to increase therapeutic doses delivered to the tumor while reducing healthy tissue exposure.
“Regardless of patient immobilization, both the tumor and adjacent critical structures may move during treatment delivery. Historically, this has presented a significant challenge in delivering highly targeted treatments,” says Dee Mathieson, Senior Vice President, Oncology Business Line Management. “Imaging in real time as the treatment is delivered demonstrates yet another leap forward in Elekta’s long history of pioneering image guidance capabilities.”
“On a second by second basis, the precise location of the tumor and sensitive healthy structures can now be visualized,” she adds “helping clinicians accurately deliver dose to the tumor while minimizing normal tissue exposure. It is a major advantage for patient safety and clinical effectiveness.”
Uniquely, Elekta’s XVI, which is also available on other Elekta radiotherapy delivery systems, includes 2D, 3D and 4D intra-fraction imaging to support live imaging during sophisticated delivery techniques, such as Volumetric Modulated Arc Therapy (VMAT).
The new capabilities within XVI include seamless integration with Elekta’s MOSAIQ(®) image-enabled oncology information system. XVI and MOSAIQ work in harmony to deliver elegant, highly automated imaging workflow for improved control, efficiency and performance. With image data available within the Oncology Information System, patient images, setup and correction data can be accessed as an integral part of the patient’s electronic medical record.
For more information, visit www.elekta.com/XVI.
XVI 5.0 is pending FDA 510(k) clearance and not yet available for sale in the U.S. Versa HD is not available for sale or distribution in all markets. Please contact your local representative for more details.
For further information, please contact:
Johan Andersson, Director, Investor Relations, Elekta AB
Tel: +46 702 100 451, email: email@example.com
Time zone: CET: Central European Time
Michelle Joiner, Director, Global Public Relations and Brand Management, Elekta
Tel: +1 770-670-2447, email: firstname.lastname@example.org
Time zone: ET: Eastern Time
Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care. Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both healthcare providers and patients, Elekta aims to improve, prolong and even save patient lives.
Today, Elekta solutions in oncology and neurosurgery are used in over 6,000 hospitals worldwide. Elekta employs around 3,500 employees globally. The corporate headquarters is located in Stockholm, Sweden, and the company is listed on the Nordic Exchange under the ticker EKTAb. Website: www.elekta.com.